Meridian Management’s Marker Therapeutics MRKR Stock Holding History

Meridian Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,956	Closed	-$9K	–	81
2022 Q1	$9K	Buy	+1,956	New	+$11.2K	﹤0.01%	84
2021 Q2	–	Sell	-1,956	Closed	-$44K	–	83
2021 Q1	$44K	Buy	1,956 +175	+10%	+$4K	0.01%	78
2020 Q4	$26K	Hold	1,781	–	–	0.01%	79
2020 Q3	$27K	Hold	1,781	–	–	0.01%	76
2020 Q2	$37K	Buy	1,781 +131	+8%	+$2.87K	0.02%	73
2020 Q1	$31K	Buy	1,650 +475	+40%	+$12.1K	0.01%	66
2019 Q4	$34K	Buy	+1,175	New	+$42.7K	0.01%	75

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Meridian Management's MRKR Position: Q2 2022 in Review

Meridian Management sold out of Marker Therapeutics (MRKR) in Q2 2022, closing a stake of 1,956 shares — an estimated $9K sold.

Meridian Management first reported a position in MRKR in Q4 2019 and held it in 7 quarters. The position peaked at $44K in Q1 2021. 48 funds tracked by Wall St. Rank hold MRKR as of Q2 2022.

Meridian Management reported no remaining Marker Therapeutics position as of Q2 2022 after selling out during the quarter.
Meridian Management sold 1,956 Marker Therapeutics shares in Q2 2022, an estimated $9K.
Meridian Management first reported a position in Marker Therapeutics in Q4 2019 and held it in 7 quarters.
Meridian Management's Marker Therapeutics position peaked at $44K in Q1 2021.
48 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2022.

Based on Meridian Management's 13F filing for Q2 2022, filed 5 Aug 2022.